Kodiak Sciences (KOD)
NASDAQ:KOD
Want to see KOD full AI Analyst Report?
KOD Stock Chart & Stats
$44.90
-$0.42(-4.39%)
At close: 4:00 PM EST
$44.90
-$0.42(-4.39%)
Day’s Range― - ―
52-Week Range$3.51 - $47.84
Previous CloseN/A
Volume87.32K
Average Volume (3M)701.52K
Market Cap
$2.26B
Enterprise Value$1.88B
Total Cash (Recent Filing)$169.53M
Total Debt (Recent Filing)$155.99M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 19, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding62,578,440
10 Day Avg. Volume791,610
30 Day Avg. Volume701,522
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.45
Price to Sales (P/S)0.00
P/FCF Ratio-10.90
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.34
Forecast
1Y Price Target
$62.67Price Target Upside39.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.74
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 GLOW2 Results (Zenkuda)The robust GLOW2 Phase 3 topline—marked efficacy, favorable safety and durable six‑month dosing—meaningfully raises the probability of a successful BLA and commercial viability. Over the medium term this improves revenue potential, supports multi‑indication expansion and strengthens the program's competitive positioning in retinal therapeutics.
Platform: Extended‑durability Antibody BiologicsKodiak’s platform engineering for extended ocular durability is a structural competitive advantage: longer dosing intervals reduce treatment burden, improve adherence, and can lower lifetime treatment costs. As a repeatable technology across indications, it provides durable differentiation and scalable commercial opportunities if clinical success continues.
Governance And Management Continuity Supported By ShareholdersStrong shareholder support for directors, executive compensation and auditor ratification signals governance stability and investor confidence in current leadership. This continuity reduces execution risk through regulatory filings, potential launch planning and complex commercialization decisions, aiding longer‑term strategic consistency.
Bears Say
No Revenue; Large Recurring Net LossesKodiak remains a pre‑revenue biotech with materially negative earnings, so profitability depends entirely on successful commercialization. Large recurring losses mean the firm must rely on external financing until product sales ramp, increasing dilution risk and delaying any improvement in operating leverage and sustainable cash generation.
Material Negative Operating And Free Cash FlowConsistently negative operating and free cash flow indicate real cash burn tied to R&D and operations. Over the medium term this elevates funding risk and the need for fresh capital to support filings, manufacturing scale‑up, or launches—potentially forcing dilutive financings or constraining commercialization investments if uptake is slower than planned.
Eroding Equity Base Limits Financial FlexibilityA sharply reduced equity base weakens balance sheet resilience despite moderate leverage. With less equity cushion, Kodiak has diminished non‑dilutive financing options and increased sensitivity to setbacks, raising the probability that future capital raises will be dilutive or costly and constraining strategic optionality during commercialization.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences’s price range in the past 12 months?
Kodiak Sciences lowest stock price was $3.51 and its highest was $47.84 in the past 12 months.
What is Kodiak Sciences’s market cap?
Kodiak Sciences’s market cap is $2.26B.
When is Kodiak Sciences’s upcoming earnings report date?
Kodiak Sciences’s upcoming earnings report date is Aug 19, 2026 which is in 59 days.
How were Kodiak Sciences’s earnings last quarter?
Currently, no data Available
Is Kodiak Sciences overvalued?
According to Wall Street analysts Kodiak Sciences’s price is currently Undervalued.
Does Kodiak Sciences pay dividends?
Kodiak Sciences does not currently pay dividends.
What is Kodiak Sciences’s EPS estimate?
Kodiak Sciences’s EPS estimate is -0.96.
How many shares outstanding does Kodiak Sciences have?
Kodiak Sciences has 62,578,440 shares outstanding.
What happened to Kodiak Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kodiak Sciences?
Currently, no hedge funds are holding shares in KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.67 (39.57% Upside)
$62.67 (39.57% Upside)
Blogger Sentiment
Bullish
KOD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 868.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
923.79%
12-Months-Change
Fundamentals
Return on Equity
-253.85%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Company Description
Kodiak Sciences
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
KOD Stock 12 Month Forecast
Average Price Target
$62.67
▲(39.57% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
33.51% Insiders
9.69% Mutual Funds
5.00% Other Institutional Investors
41.39% Public Companies and
Individual Investors